相关实验视频
Updated: May 9, 2025
13:28
Methodology for Sputum Induction and Laboratory Processing
Published on: December 17, 2017
27.3K
梅波利祖马布用于COPD与eosinophilic表型在住院治疗后
Cara A Flynn1, Hamish J C McAuley1, Omer Elneima1
1Institute for Lung Health, National Institute for Health and Care Research Leicester Biomedical Research Centre, University Hospitals of Leicester NHS Trust and University of Leicester, UK.
NEJM evidence
|April 30, 2025
概括
梅波利祖马布并没有减少患有慢性阻塞性肺病 (AECOPD) 急性恶化和eosinophilic炎症的住院患者的再入院或死亡. 虽然恶化症略有减少,但主要结局显示这种COPD生物治疗没有显著的益处.
科学领域:
- 肺部病理学 肺部病理学
- 免疫学 免疫学 免疫学
- 临床试验 临床试验
背景情况:
- 慢性阻塞性肺病 (AECOPD) 的急性恶化带有高发病率和死亡率风险.
- 针对eosinophilic炎症的生物疗法可以减少COPD恶化.
- 梅波利祖马布 (Mepolizumab) 是一种抗素5单克隆抗体,可降低乙酸性炎症,但其对AECOPD住院和死亡率的影响尚不清楚.
研究的目的:
- 评估梅波利祖马布在减少AECOPD和eosinophilic炎症患者住院再入院或死亡的疗效.
- 评估梅波利祖马布对这种患者群体恶化率和与健康有关的生活质量的影响.
主要方法:
- 一个2b期,双盲,安慰剂对照试验,涉及238名患者住院治疗AECOPD和升高的血红蛋白 (≥300细胞/μL在前12个月).
- 患者每4周服用100毫克梅波利祖马布或安慰剂,每4周服用48周,医院出院后开始治疗.
- 主要终点:重新入院或死亡的时间. 二级终点:再入院人数,恶化和生活质量.
主要成果:
- 梅波利祖马布和安慰剂组之间住院或死亡的中位时间没有显著差异 (25.4 vs 26.1周;HR,0.96;P=0.811).
- 梅波利祖马布显示出减少住院再接收的趋势 (RR,0.89),以及中度或严重恶化的统计显著减少 (RR,0.81).
- 两组之间不良事件的发生率相似,没有严重的不良事件归因于mepolizumab.
结论:
- 在48周的Mepolizumab治疗中,没有显示出降低患有eosinophilic炎症的住院AECOPD患者再入院或死亡风险的益处.
- 观察到的减轻中度或严重恶化的趋势需要进一步调查,与之前的试验结果保持一致.
- 这项研究表明,在这个特定的AECOPD亚组中,美波利祖马布可能无法有效预防未来住院治疗或死亡.
相关概念视频
01:26COPD: Management Using Bronchodilators and Corticosteroids
117
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
117
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
151
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
151
01:30Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
01:17Drugs Used in Lower Respiratory Disorders: Overview
242
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
242
01:20COPD: Pathogenesis and Clinical Features
170
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
170
01:29Chronic Obstructive Pulmonary Disease-V: Management
2.5K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.5K